Ikerbasque, Fundación Vasca para la Ciencia-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors (Scientific Reports, (2018), 8, 1, (12746), 10.1038/s41598-018-30836-5)

    Scientific Reports

  2. Chaperone-Mediated Autophagy Controls Proteomic and Transcriptomic Pathways to Maintain Glioma Stem Cell Activity

    Cancer Research, Vol. 82, Núm. 7, pp. 1283-1297

2020

  1. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Liquid biopsy in glioblastoma: Opportunities, applications and challenges

    Cancers, Vol. 11, Núm. 7

2018

  1. PR-LncRNA signature regulates glioma cell activity through expression of SOX factors

    Scientific Reports, Vol. 8, Núm. 1

  2. Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases

    F1000Research, Vol. 6

2017

  1. High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response

    Oncogenesis, Vol. 6, Núm. 12

2016

  1. MTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance

    Expert Opinion on Therapeutic Targets, Vol. 20, Núm. 4, pp. 393-405

  2. Targeting SOX2 as a therapeutic strategy in glioblastoma

    Frontiers in Oncology

2013

  1. Therapeutic strategies targeting Glioblastoma stem cells

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 8, Núm. 3, pp. 216-227